ARTICLE | Management Tracks
Plus: John McDonough to resign as chairman from BioPorto, and updates from Caris, FibroGen, Akari and Xilio
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
December 18, 2024 12:55 AM UTC
David Apelian has become CEO of Theolytics Ltd., which is developing oncolytic immunotherapies. Apelian was CEO of BlueSphere Bio Inc. and CMO of Achillion Pharmaceuticals Inc.
John McDonough will resign as chairman of BioPorto A/S (CSE:BIOPOR) no later than the company’s next annual general meeting. McDonough will continue in his role until a successor has been nominated…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654510/david-apelian-becomes-ceo-of-theolytics